News
-
Isis Adds Three New Drugs To Its Development Pipeline
12/16/2011
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has added three new drugs to its development pipeline, ISIS-APOARx, ISIS-DGAT2Rx and ISIS-FVIIRx.
-
Simcere And Bristol-Myers Squibb Enter Innovative Partnership To Develop Cardiovascular Compound
12/15/2011
Bristol-Myers Squibb Company (NYSE: BMY) and Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company in China, today announced that the companies have expanded the strategic partnership formed last year to include a second collaboration in a different therapeutic area.
-
Novartis Gains European Commission Approval For Rasitrio, A Rasilez-Based Triple Combination Pill To Treat High Blood Pressure
11/29/2011
Novartis announced recently that Rasitrio, the first triple combination of aliskiren, amlodipine and hydrochlorothiazide (HCT) in a single pill,1 has received approval from the European Commission (EC) for the treatment of high blood pressure.
-
The Cardiovascular Research Foundation And The Angiographic Core Laboratory Of Harvard Medical Faculty Physicians At Beth Israel Deaconess Medical Center, Inc. Announce CRFiCOR, A Collaborative Alliance To Enhance Patient Care
11/8/2011
The Angiographic and Imaging Core Laboratories of the Clinical Trials Center (CTC) at the Cardiovascular Research Foundation (CRF) in New York have formed a collaborative alliance with the Angiographic Core Laboratory of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center, Inc. (HFMP).
-
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use In 45% Of Patients With Serious Form Of Childhood Arthritis
11/8/2011
Novartis announced recently new pivotal Phase III data showing 45% of children with active systemic juvenile idiopathic arthritis (SJIA) were able to substantially reduce their use of oral corticosteroids (often described as steroids) within 28 weeks of commencing treatment with ACZ885 (canakinumab) (p<0.0001).
-
World Precision Instruments Launches Cell Tester - Unique Cell Biology Tool To Sense Stress And Stretch In Individual Cells
11/2/2011
World Precision Instruments Inc recently announced the launch of the new Cell Tester, a novel cell biology research tool, set to revolutionize the emerging field of ‘mechano transduction’ by allowing researchers to study the influence of mechanical force, stress or strain on cells and how these cells react to stimuli.
-
Agilent Technologies Supports Research At The Broad Institute, Developing Proteomics Technology To Detect Disease Biomarkers
10/13/2011
Agilent Technologies Inc. and the Agilent Technologies Foundation recently announced that Steven Carr, Ph.D, who directs the Proteomics Platform at the Broad Institute of MIT and Harvard, has been selected for an Agilent Thought Leader Award supporting his work developing new technology for analyzing proteins and peptides.
-
Santaris Pharma A/S To Report New Clinical Data From Miravirsen Phase 2a Study To Treat Hepatitis C In Late-Breaking Oral Presentation At The AASLD 2011 Annual Meeting
10/4/2011
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA and mRNA-targeted therapies, today announced the Company will report new clinical data results from the miravirsen Phase 2a proof-of-concept study to treat patients infected with the Hepatitis C virus (HCV) in a late-breaking oral presentation session at the American Association for the Study of Liver Diseases (AASLD) 2011 annual meeting.
-
BARDA Funds Development Of Five Drugs To Protect Against Radiation
9/30/2011
The development of five new drugs to treat injuries associated with acute radiation syndrome will move forward under contracts awarded by the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA).
-
Novartis Study Showed ACZ885 Provided Substantial Symptom Relief In 84% Of Patients With The Most Serious Form Of Childhood Arthritis
9/21/2011
Novartis announced recently positive results of the first pivotal Phase III trial of ACZ885 (canakinumab) in patients with systemic juvenile idiopathic arthritis (SJIA), a rare and serious childhood auto-inflammatory disease.
This website uses cookies to ensure you get the best experience on our website. Learn more